Compound from Centella asiatica Stops Drug-Resistant Bacteria in Lab Tests
Researchers reported that madecassic acid — derived from the long-used herb Centella asiatica — disrupts drug-resistant bacterial infections in lab studies, suggesting a new lead against the antimicrobial-resistance crisis.
HealthGNGV Editorial Team4 min readLast reviewed September 28, 2026
Antimicrobial resistance is one of the most stubborn health challenges of the decade, contributing to more than a million deaths a year. A new study highlighted by ScienceDaily in April 2026 suggests an unexpected ally: madecassic acid, a triterpenoid compound extracted from Centella asiatica, a commonly used Asian medicinal herb.
In laboratory experiments, madecassic acid disrupted multiple drug-resistant bacterial strains by interfering with virulence pathways and biofilm formation rather than killing bacteria outright. That mechanism is intriguing because it could reduce selection pressure for further resistance — bacteria are less likely to evolve around a drug that disarms them rather than kills them.
The plant has been used for centuries in India, China and Southeast Asia for wound healing and skin conditions; modern science is now isolating its active molecules. The April work adds to a growing pipeline of plant-derived compounds being repurposed for stubborn infections, including methicillin-resistant Staphylococcus aureus (MRSA) and gram-negative pathogens that resist most modern antibiotics.
Researchers stress that animal studies and clinical trials are required before madecassic acid can be developed into a medicine. Still, in a field where breakthroughs are rare, finding a hopeful lead in a humble traditional herb is a quiet but meaningful piece of good news for global health.
